Thus, anti-PD-L1 monoclonal antibodies (mAbs), such as atezolizumab, and anti-PD-1 mAbs, such as pembrolizumab and nivolumab, are effective against many cancer types and show a favorable 5-year survival rate for cancer patients. This evidence concerns the gene PDCD1 and cancer.